What’s Fueling Optimism Around Ardelyx, Inc. (ARDX)’s Sales and Pipeline?
Key takeaways
- Rameen Kasana Tue, June 23, 2026 at 10:36 PM GMT+7 2 min read ARDX Ardelyx, Inc.
- (NASDAQ:ARDX) reported its Q1 FY2026 results, its total product revenue was up 38% YoY, thanks to 58% YoY surge in IBSRELA revenue and strong XPHOZAH performance.
- As stated by the President and CEO, Mike Raab,
What’s Fueling Optimism Around Ardelyx, Inc. (ARDX)’s Sales and Pipeline? Rameen Kasana Tue, June 23, 2026 at 10:36 PM GMT+7 2 min read ARDX Ardelyx, Inc. (NASDAQ:ARDX) is among the best low priced stocks to get rich in 2026. On June 16, Ladenburg started coverage on Ardelyx, Inc. (NASDAQ:ARDX) with a Buy rating and a price target of $16. According to The Fly, the company is currently focused on expanding demand for Ibsrela, sustaining sales momentum for Xphozah, growing its pipeline, and meeting financial projections.
When Ardelyx, Inc. (NASDAQ:ARDX) reported its Q1 FY2026 results, its total product revenue was up 38% YoY, thanks to 58% YoY surge in IBSRELA revenue and strong XPHOZAH performance. While discussing IBSRELA, management laid out plans to deliver at least $1 billion in annual revenue in 2029. What strengthens the case for the company is its financial flexibility to make additional investments.
As stated by the President and CEO, Mike Raab,